Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma
Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This is a single-center, single-arm, phase 2 study to evaluate the efficacy and safety of
Anti-PD-1 antibody(Sintilimab) plus HDAC inhibitor(Chidamide) in patients with
relapsed/refractory peripheral T-cell lymphoma (r/r PTCL).